The drugmaker could not produce statistically significant data on whether the nation’s most prescribed COVID-19 treatment was effective in reducing the risk of hospitalizations and deaths, according to a June 14 news release.
The results hit a snag in Paxlovid’s already murky progress, which recently faced discrepancies over rebound symptoms. The CDC warned May 25 symptoms could reappear between two to eight days after testing negative, while the Mayo Clinic said June 14 that the risk is rare.
The company said in the release that it plans to continue testing Paxlovid’s efficacy in high-risk populations.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
